No Prescription |
 |
 | ||
|
Lamisil Derm Gel Generic Terbinafine |
|
| ||
No Prescription » Prescription Drugs 9 » Lamisil Derm Gel Generic Terbinafine Therapeutic indications:1. Onychomycosis (fungal infection of the nail) caused by dermatophyte fungi. 2. Tinea capitis. 3. Fungal infections of the skin for the treatment of tinea corporis tinea cruris tinea pedis and yeast infections of the skin caused by the genus Candida (e.g. Candida albicans) where oral therapy is generally considered appropriate owing to the site severity or extent of the infection. Note: In contrast to topical Lamisil« oral Lamisil is not effective in pityriasis versicolor.Skin infectionsRecommended duration of treatment:Tinea pedis (interdigital plantar/moccasin type): 2 to 6 weeks.Tinea corporis cruris: 2 to 4 weeks.Cutaneous candidiasis: 2 to 4 weeks.Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.Hair and scalp infectionsRecommended duration of treatment:Tinea capitis: 4 weeks.Tinea capitis occurs primarily in children.OnychomycosisFor most patients the duration of successful treatment is 6-12 weeks.Fingernail onychomycosisSix weeks of therapy is sufficient for fingernail infections in most cases.Toenail onychomycosisTwelve weeks of therapy is sufficient for toenail infections in most cases.Some patients with poor nail outgrowth may require longer treatment. The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail. Buy Lamisil Derm Gel Generic Terbinafine and other Prescription Drugs 9 products online at Medstore. 5524
About Lamisil Derm Gel Generic Terbinafine: Product Type: Prescription Drugs 9 Lamisil Derm Gel ( Generic Terbinafine ) Lamisil Derm Gel (Generic Terbinafine) Generic Terbinafine 1% 15gm Generic Terbinafine Lamisil Derm Gel
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
